{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:38:28Z","timestamp":1787891908006,"version":"build-2784847793"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,30]]},"DOI":"10.7759\/cureus.25477","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T12:42:36Z","timestamp":1653914556000},"source":"Crossref","is-referenced-by-count":2,"title":["Demographic and Geospatial Analysis of Buprenorphine and Methadone Prescription Rates"],"prefix":"10.7759","author":[{"given":"Nicholas J","family":"Peterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Palsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aksal","family":"Vashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejal","family":"Vashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley D","family":"Kaptur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhae","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Mccauley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Centers for Disease Control and Prevention. WONDER. (2020). https.\/\/wonder.cdc.gov\/."},{"key":"ref2","unstructured":"Key substance use and mental health indicators in the United States. results from the 2019 National Survey on Drug Use and Health. (2020). https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt29393\/2019NSDUHFFRPDFWHTML\/2019NSDUHFFR090120.htm."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","author":"American Society of Addiction Medicine","year":"2020","unstructured":"American Society of Addiction Medicine. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med. 2020, 14:1-91. 10.1097\/ADM.0000000000000633","journal-title":"J Addict Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.17226\/25310","article-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences","year":"2019","unstructured":"National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. Leshner AI, Mancher M (ed): National Academies Press, Washington, DC; 2019. 10.17226\/25310"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.13113","article-title":"County-level access to opioid use disorder medications in Medicare part D (2010-2015)","volume":"54","author":"Abraham AJ","year":"2019","unstructured":"Abraham AJ, Adams GB, Bradford AC, Bradford WD. County-level access to opioid use disorder medications in Medicare part D (2010-2015). Health Serv Res. 2019, 54:390-8. 10.1111\/1475-6773.13113","journal-title":"Health Serv Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2021.100451","article-title":"Buprenorphine X-waiver exemption - beyond the basics for the obstetrical provider","volume":"3","author":"Cleary EM","year":"2021","unstructured":"Cleary EM, Smid MC, Charles JE, Jones KM, Costantine MM, Saade G, Rood KM. Buprenorphine X-waiver exemption - beyond the basics for the obstetrical provider. Am J Obstet Gynecol MFM. 2021, 3:100451. 10.1016\/j.ajogmf.2021.100451","journal-title":"Am J Obstet Gynecol MFM"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15123","article-title":"The end of the X-waiver: not a moment too soon!","volume":"13","author":"Pergolizzi J","year":"2021","unstructured":"Pergolizzi J, LeQuang JA, Breve F. The end of the X-waiver: not a moment too soon!. Cureus. 2021, 13:e15123. 10.7759\/cureus.15123","journal-title":"Cureus"},{"key":"ref8","article-title":"Vital signs: overdoses of prescription opioid pain relievers and other drugs among women \u2014 United States, 1999-2010","volume":"62","author":"Mack KA","year":"2013","unstructured":"Mack KA, Jones CM, Paulozzi LJ. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women \u2014 United States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2013, 62:537-42.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.16281","article-title":"Help is on the way: Medicare coverage of opioid treatment programs","volume":"68","author":"Felix C","year":"2020","unstructured":"Felix C, Sharfstein JM, Olsen Y. Help is on the way: Medicare coverage of opioid treatment programs. J Am Geriatr Soc. 2020, 68:637-40. 10.1111\/jgs.16281","journal-title":"J Am Geriatr Soc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.10.001","article-title":"Emergence of methadone as a street drug in St. Petersburg, Russia","volume":"27","author":"Heimer R","year":"2016","unstructured":"Heimer R, Lyubimova A, Barbour R, Levina OS. Emergence of methadone as a street drug in St. Petersburg, Russia. Int J Drug Policy. 2016, 27:97-104. 10.1016\/j.drugpo.2015.10.001","journal-title":"Int J Drug Policy"},{"key":"ref11","article-title":"Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone?","volume":"63","author":"Srivastava A","year":"2017","unstructured":"Srivastava A, Kahan M, Nader M. Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone?. Can Fam Physician. 2017, 63:200-5.","journal-title":"Can Fam Physician"},{"key":"ref12","unstructured":"The SUPPORT for Patients and Communities Act of 2018. (2018). https.\/\/www.aha.org\/system\/files\/2018-10\/181024-legislative-adv-patients-and-communities-act.pdf."},{"key":"ref13","unstructured":"ARCOS Registrant Handbook. (1997). https.\/\/web.archive.org\/web\/20161229223436\/https:\/\/www.deadiversion.usdoj.gov\/arcos\/handbook\/index.html."},{"key":"ref14","unstructured":"ARCOS Retail Drug Summary Reports. (2021). https.\/\/www.deadiversion.usdoj.gov\/arcos\/retail_drug_summary\/#:~:text=Automated%20Reports%20and%20Consolidated%20Orde...."},{"key":"ref15","unstructured":"How to download and use the DEA pain pills database. (2019). https.\/\/www.washingtonpost.com\/national\/2019\/07\/18\/how-download-use-dea-pain-pills-database\/."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2017.304265","article-title":"Quantifying the epidemic of prescription opioid overdose deaths","volume":"108","author":"Seth P","year":"2018","unstructured":"Seth P, Rudd RA, Noonan RK, Haegerich TM. Quantifying the epidemic of prescription opioid overdose deaths. Am J Public Health. 2018, 108:500-2. 10.2105\/AJPH.2017.304265","journal-title":"Am J Public Health"},{"key":"ref17","article-title":"Drug overdose deaths among adolescents aged 15-19 in the United States: 1999-2015","author":"Curtin SC","year":"2017","unstructured":"Curtin SC, Tejada-Vera B, Warmer M. Drug overdose deaths among adolescents aged 15-19 in the United States: 1999-2015. NCHS Data Brief. 2017, 1-8.","journal-title":"NCHS Data Brief"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.23907\/2013.029","article-title":"State variation in certifying manner of death and drugs involved in drug intoxication deaths","volume":"3","author":"Warner M","year":"2013","unstructured":"Warner M, Paulozzi LJ, Nolte KB, Davis GG, Nelson LS. State variation in certifying manner of death and drugs involved in drug intoxication deaths. Acad Forensic Pathol. 2013, 3:231-7. 10.23907\/2013.029","journal-title":"Acad Forensic Pathol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2021.106779","article-title":"County-level data on U.S. opioid distributions, demographics, healthcare supply, and healthcare access","volume":"35","author":"Griffith KN","year":"2021","unstructured":"Griffith KN, Feyman Y, Auty SG, Crable EL, Levengood TW. County-level data on U.S. opioid distributions, demographics, healthcare supply, and healthcare access. Data Brief. 2021, 35:106779. 10.1016\/j.dib.2021.106779","journal-title":"Data Brief"},{"key":"ref20","unstructured":"Urban Influence Codes. (2021). https.\/\/www.ers.usda.gov\/data-products\/urban-influence-codes\/."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6373","article-title":"Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder","volume":"2","author":"Haffajee RL","year":"2019","unstructured":"Haffajee RL, Lin LA, Bohnert AS, Goldstick JE. Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Netw Open. 2019, 2:e196373. 10.1001\/jamanetworkopen.2019.6373","journal-title":"JAMA Netw Open"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14555","article-title":"Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas\u2014United States","volume":"17","author":"Mack KA","year":"2017","unstructured":"Mack KA, Jones CM, Ballesteros MF. Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas\u2014United States. Am J Transplant. 2017, 17:3241-52. 10.1111\/ajt.14555","journal-title":"Am J Transplant"},{"key":"ref23","unstructured":"CDC. Data user agreement. (2020). Accessed. August 4, 2021: https:\/\/www.cdc.gov\/nchs\/data_access\/restrictions.htm."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12963-015-0044-2","article-title":"The County Health Rankings: rationale and methods","volume":"13","author":"Remington PL","year":"2015","unstructured":"Remington PL, Catlin BB, Gennuso KP. The County Health Rankings: rationale and methods. Popul Health Metr. 2015, 13:11. 10.1186\/s12963-015-0044-2","journal-title":"Popul Health Metr"},{"key":"ref25","article-title":"Managing opioid addiction with buprenorphine","volume":"73","author":"Donaher PA","year":"2006","unstructured":"Donaher PA, Welsh C. Managing opioid addiction with buprenorphine. Am Fam Physician. 2006, 73:1573-8.","journal-title":"Am Fam Physician"},{"key":"ref26","unstructured":"Opioid oral morphine milligram equivalent (MME) conversion factors. (2017). https.\/\/medicaid.utah.gov\/Documents\/files\/Opioid-Morphine-EQ-Conversion-Factors.pdf."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-03647-7_5","article-title":"GeoDa: an introduction to spatial data analysis","author":"Anselin L","year":"2010","unstructured":"Anselin L, Syabri I, Kho Y. GeoDa: an introduction to spatial data analysis. Handbook of Applied Spatial Analysis. Fischer M, Getis A (ed): Springer, Berlin, Heidelberg; 2010. 73-89. 10.1007\/978-3-642-03647-7_5"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2307\/2332142","article-title":"Notes on continuous stochastic phenomena","volume":"37","author":"Moran PAP","year":"1950","unstructured":"Moran PAP. Notes on continuous stochastic phenomena. Biometrika. 1950, 37:17-23. 10.2307\/2332142","journal-title":"Biometrika"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-4632.1995.tb00338.x","article-title":"Local indicators of spatial association\u2014LISA","volume":"27","author":"Anselin L","year":"1995","unstructured":"Anselin L. Local indicators of spatial association\u2014LISA. Geogr Anal. 1995, 27:93-115. 10.1111\/j.1538-4632.1995.tb00338.x","journal-title":"Geogr Anal"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2020.106625","article-title":"Racial\/ethnic differences in US drug overdose mortality, 2017-2018","volume":"112","author":"Cano M","year":"2021","unstructured":"Cano M. Racial\/ethnic differences in US drug overdose mortality, 2017-2018. Addict Behav. 2021, 112:106625. 10.1016\/j.addbeh.2020.106625","journal-title":"Addict Behav"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000001299","article-title":"Spatiotemporal trends in opioid overdose deaths by race for counties in Ohio","volume":"32","author":"Kline D","year":"2021","unstructured":"Kline D, Pan Y, Hepler SA. Spatiotemporal trends in opioid overdose deaths by race for counties in Ohio. Epidemiology. 2021, 32:295-302. 10.1097\/EDE.0000000000001299","journal-title":"Epidemiology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1080\/15265161.2017.1353176","article-title":"Not by proxy: arguments for improving the use of race in biomedical research","volume":"17","author":"Neal K","year":"2017","unstructured":"Neal K. Not by proxy: arguments for improving the use of race in biomedical research. Am J Bioeth. 2017, 17:52-4. 10.1080\/15265161.2017.1353176","journal-title":"Am J Bioeth"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1053\/apmr.2002.35115","article-title":"Race: predictor versus proxy variable? Outcomes after spinal cord injury","volume":"83","author":"Putzke JD","year":"2002","unstructured":"Putzke JD, Hicken BL, Richards JS. Race: predictor versus proxy variable? Outcomes after spinal cord injury. Arch Phys Med Rehabil. 2002, 83:1603-11. 10.1053\/apmr.2002.35115","journal-title":"Arch Phys Med Rehabil"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s13524-011-0047-y","article-title":"The determinants of neighborhood satisfaction: racial proxy revisited","volume":"48","author":"Swaroop S","year":"2011","unstructured":"Swaroop S, Krysan M. The determinants of neighborhood satisfaction: racial proxy revisited. Demography. 2011, 48:1203-29. 10.1007\/s13524-011-0047-y","journal-title":"Demography"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/97514-demographic-and-geospatial-analysis-of-buprenorphine-and-methadone-prescription-rates","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:11Z","timestamp":1707507371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/97514-demographic-and-geospatial-analysis-of-buprenorphine-and-methadone-prescription-rates"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.25477","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,30]]}}}